ObsEva SA (NASDAQ:OBSV, SIX: OBSN))))), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each. The 20,000,000 new shares, to be issued out of the company’s authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around December 12, 2022. The transaction has been decided to provide the group with additional treasury shares that can be used in the future to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.
Zevia Q2 Sales $45.50M Beat $42.17M Estimate
Zevia (NYSE:ZVIA) reported quarterly sales of $45.50 million which beat the analyst consensus estimate of $42.17 million by 7.90 percent. This is a 32.45 percent increase over sales of $34.35 million the same period
